A phase Ib/II trial was conducted to assess the efficacy of ribociclib + letrozole, alpelisib + letrozole, and ribociclib + alpelisib + letrozole treatment in ER+ HER2− BC patients. This evidence concerns the gene ERBB2 and breast cancer.